- Who We ServeWho We Serve
- SolutionsSolutions
- Patient ImpactPatient Impact
- InsightsInsights
- About UsAbout Us
CoverMyMeds joined thousands of industry leaders at Asembia’s AXS25 Summit to explore healthcare innovation and collaboration. This year was especially impactful, and we captured key insights in our Barrier Breaker podcast series, featuring real-time takeaways from CoverMyMeds’ leaders.
CoverMyMeds connects you throughout the access and reimbursement process, so you can get therapies to patients faster than with traditional phone and fax methods.[0]CoverMyMeds data on file, 2025.
At AXS25, we showed you how — breaking down barriers between pharma, providers, pharmacies, and payers; helping reduce complexities of medication access; and shaping the future of your program. Here’s how we make an impact every day:
Each day at Asembia’s AXS25 Summit, we hit record on the real conversations shaping healthcare right now. Catch every short, insightful episode here.
Presented at AXS25 | Wednesday, April 30
The goal of the Inflation Reduction Act (IRA) is to reduce pricing for patients and improve access to needed medicines. However, whether this outcome will be achieved and the broader impact this will have on the industry is still unknown. This session examined how the changes necessitated by the IRA may be implemented across the value chain, as well as the anticipated impacts for pharma companies, payers, pharmacies, providers and patients. Panelists also broadened the affordability discussion beyond individual drugs, exploring the overall cost of a patient's care and the influence of social determinants of health on outcomes.
H. John Beardsley is Senior Vice President of Corporate Strategy and Business Development at CoverMyMeds. In this role, John is responsible for analyzing market trends and investigating potential partnerships that can yield greater value for customers and patients. John has more than 25 years of experience in health insurance, pharmacy, financial services, and healthcare technology. Throughout his career, he has focused on strengthening the connections between pharmacies, health systems, insurers and pharma companies to improve patient care.
Ashwin Singhania has over 20 years of experience in life sciences advising biopharma companies to support their strategic growth in bringing new products to market to enhance patient care. As a principal within Strategy and Transactions at EY-Parthenon, Ernst & Young LLP, Ashwin focuses on corporate and commercial strategy for biopharma across growth strategy, transaction support and operating model transformation. His career includes roles with large pharmaceutical organizations, specialty pharmaceuticals and prerevenue biotechs. He also supports private equity for investments in biopharmaceutical and biopharmaceutical services.
Fauzea Hussain is the Vice President of Public Policy at McKesson, where she champions public policy strategies that drive the company's mission to improve health outcomes. With a keen focus on patient-first solutions, Fauzea collaborates across the enterprise to address the diverse needs of distributors, wholesalers, community providers, health systems, pharmacies, manufacturers, technology vendors and consumers. A seasoned policy expert with over 25 years of experience, Fauzea has a proven track record in assessing the impact of state and federal policies on patient access, provider reimbursement, and the life sciences industry.
H. John Beardsley is Senior Vice President of Corporate Strategy and Business Development at CoverMyMeds. In this role, John is responsible for analyzing market trends and investigating potential partnerships that can yield greater value for customers and patients. John has more than 25 years of experience in health insurance, pharmacy, financial services, and healthcare technology. Throughout his career, he has focused on strengthening the connections between pharmacies, health systems, insurers and pharma companies to improve patient care.
Ashwin Singhania has over 20 years of experience in life sciences advising biopharma companies to support their strategic growth in bringing new products to market to enhance patient care. As a principal within Strategy and Transactions at EY-Parthenon, Ernst & Young LLP, Ashwin focuses on corporate and commercial strategy for biopharma across growth strategy, transaction support and operating model transformation. His career includes roles with large pharmaceutical organizations, specialty pharmaceuticals and prerevenue biotechs. He also supports private equity for investments in biopharmaceutical and biopharmaceutical services.
Fauzea Hussain is the Vice President of Public Policy at McKesson, where she champions public policy strategies that drive the company's mission to improve health outcomes. With a keen focus on patient-first solutions, Fauzea collaborates across the enterprise to address the diverse needs of distributors, wholesalers, community providers, health systems, pharmacies, manufacturers, technology vendors and consumers. A seasoned policy expert with over 25 years of experience, Fauzea has a proven track record in assessing the impact of state and federal policies on patient access, provider reimbursement, and the life sciences industry.
